Fol. Biol. 2007, 53, 71-73
https://doi.org/10.14712/fb2007053030071
Gene Therapy of Cancer by Vaccines Carrying Inserted Immunostimulatory Genes
References
1. , J., Voitenok, N. N., Kieler, J., Prassolov, V. S., Chumakov, P. M., Bubeníková, D., Šímová, J., Jandlová, T. (1988) Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol. Lett. 19, 279-282.
<https://doi.org/10.1016/0165-2478(88)90155-1>
2. , J. (1989) Local immunotherapy of cancer with interleukin 2. Immunol. Lett. 21, 267-274.
<https://doi.org/10.1016/0165-2478(89)90018-7>
3. , J., Lotzová, E., Indrová, M., Šímová, J., Jandlová, T., Savary, C. A. (1991) IL-2 gene transfer in immunotherapy of cancer: local administration of IL-2-activated lymphocytes and X63-m-IL-2 cells constitutively producing IL-2 inhibits growth of plasmacytomas in syngeneic mice. Nat. Immun. Cell Growth Regul. 10, 247-255.
4. , J., Šímová, J., Bubeníková, D., Zeuthen, J., Indrová, M. (1995) Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment. J. Cancer Res. Clin. Oncol. 121, 39-43.
<https://doi.org/10.1007/BF01202727>
5. , J. (1996a) Cytokine gene-modified vaccines in the therapy of cancer. Pharmacol. Ther. 69, 1-14.
<https://doi.org/10.1016/0163-7258(95)02016-0>
6. , J. (1996b) Gene transfer for immunotherapy of cancer. Gene Ther. 3, 944-945.
7. , J., Šímová, J., Hajková, R., Sobota, V., Jandlová, T., Šmahel, M., Sobotková, E., Vonka, V. (1999) Interleukin 2 gene therapy of residual disease in mice carrying tumours induced by HPV 16. Int. J. Oncol. 14, 593-597.
8. , J. (2001) Genetically engineered dendritic cell-based cancer vaccines (Review). Int. J. Oncol. 18, 475-478.
9. , J., Mikyšková, R., Vonka, V., Mendoza, L., Šímová, J., Šmahel, M., Indrová, M. (2003) Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 21, 891-896.
<https://doi.org/10.1016/S0264-410X(02)00537-6>
10. , J., Šímová, J. (2005) Minimal residual disease as the target for immunotherapy and gene therapy of cancer (Review). Oncol. Rep. 14, 1377-1380.
11. , D., Burmester, J. K. (2006) Gene therapy for cancer treatment: past, present and future. Clin. Med. Res. 4, 218-227.
<https://doi.org/10.3121/cmr.4.3.218>
12. , C.C., Chada, S., Merritt, J. A., Tong, A., Senzer, N., Zhang, Y., Mhashilkar, A., Parker, K., Vukelja, S., Richards, D., Hood, J., Coffee, K., Nemunaitis, J. (2005) Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study. Mol. Ther. 11, 149-159.
<https://doi.org/10.1016/j.ymthe.2004.09.019>
13. , E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., Frost, P. (1990) Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60, 397-403.
<https://doi.org/10.1016/0092-8674(90)90591-2>
14. , R., Guarini, A., Cignetti, A., Cronin, K., Rosenthal, F., Gansbacher, B. (1994) Cytokine gene therapy: a new strategy for the management of cancer patients. Nat. Immun. 13, 65-75.
15. , B., Zier, K., Daniels, B., Cronin, K., Bannerji, R., Gilboa, E. (1990) Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 172, 1217-1224.
<https://doi.org/10.1084/jem.172.4.1217>
16. , B., Zier, K., Cronin, K., Hantzopoulos, P. A., Bouchard, B., Houghton, A., Gilboa, E., Golde, D. (1992) Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood 80, 2817-2825.
<https://doi.org/10.1182/blood.V80.11.2817.2817>
17. , G., Finstad, C. L., Guarini, A., Bosl, G., Gilboa, E., Bander, N. H., Gansbacher, B. (1992) Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res. 52, 6229-6236.
18. , M., Bubeník, J., Mikyšková, R., Mendoza, L., Šímová, J., Bieblová, J., Jandlová, T., Jinoch, P., Šmahel, M., Vonka, V., Pajtasz-Piasecka, E. (2003) Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I-tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines. Int. J. Oncol. 22, 691-695.
19. , T. (2006) Genetically modified dendritic cells for therapeutic immunity. Tohoku J. Exp. Med. 208, 1-8.
<https://doi.org/10.1620/tjem.208.1>
20. , V., Langlade-Demoyen, P., Kourilsky, P., Larsson-Sciard, E. L. (1991) Interleukin 2-dependent activation of tumor-specific cytotoxic T lymphocytes in vivo. Eur. J. Immunol. 21, 851-854.
<https://doi.org/10.1002/eji.1830210350>
21. , R., Bubeník, J., Mendoza, L., Vonka, V., Šmahel, M., Šímová, J., Jandlová, T. (2001) Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases. Clin. Exp. Metastasis 18, 581-587.
<https://doi.org/10.1023/A:1011987206008>
22. , R., Indrová, M., Šímová, J., Jandlová, T., Bieblová, J., Jinoch, P., Bubeník, J., Vonka, V. (2004) Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF. Int. J. Oncol. 24, 161-167.
23. , J. (2003) GVAX (GM-CSF gene modified tumor vaccine) in advanced stage non small cell lung cancer. J. Control. Release 91, 225-231.
<https://doi.org/10.1016/S0168-3659(03)00210-4>
24. , J., Jahan, T., Ross, H., Sterman, D., Richards, D., Fox, B., Jablons, D., Aimi, J., Lin, A., Hege, K. (2006) Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer. Cancer Gene Ther. 13, 555-562.
<https://doi.org/10.1038/sj.cgt.7700922>
25. , R. E., Fakhrai, H., Shawler, D., Gjerset, R., Dorigo, O., Carson, C., Khaleghi, T., Koziol, J., Shiftan, T. A., Royston, I. (1995) Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther. 2, 164-167.
